Teva seeks leave in levofloxacin damages assessment.
As previously reported, the Federal Court of Appeal (FCA) dismissed Teva’s appeal on the quantification of damages from infringement of Janssen’s patent for levofloxacin (LEVAQUIN). The FCA rejected Teva’s arguments, finding that the Federal Court did not err in constructing the hypothetical world, and that the Federal Court’s factual findings were open to it on the evidence. On March 26, 2018, Teva applied to the Supreme Court of Canada for leave to appeal (docket no. 38033).
Supreme Court denies leave regarding natural health product licence.
On April 12, 2018, the Supreme Court of Canada dismissed The Winning Combination’s leave to appeal (docket no. 37697). The Federal Court of Appeal decision had set aside the order of mandamus compelling the Minister of Health to grant a licence to The Winning Combination for its natural health product, RESOLVE (as previously reported).
Related Publications & Articles
-
Alexion awarded injunction against Amgen in SOLIRIS patent action; Court considers anticipation by incorporation by reference
The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, using, and selling its proposed biosimilar eculizumab product, BEKEMV, in Can...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More